Zhangjiang Haoheng

Zhangjiang Haoheng is a Chinese private equity firm specializing in venture capital and private equity investments across various industries and stages. The firm focuses on sectors such as technology, healthcare, biotechnology, pharmaceuticals, consumer goods, energy, environmental services, media, entertainment, education, financial services, real estate, manufacturing, retail, and logistics. It invests in companies at various stages, including seed, early stage, growth, late stage, pre-IPO, buyout, turnaround, and distressed situations. The firm is headquartered in Shanghai, China, and primarily focuses its investments within the country. Zhangjiang Haoheng has a track record of investing in over 100 businesses, many of which are listed on domestic and international capital markets. The firm has invested over 4 billion yuan in more than 125 projects to date, with a contract investment of more than 3 billion yuan in more than 50 funds. Its investment philosophy emphasizes the deep integration of incubation with investment to form an effective capital-led mechanism that helps startups improve their capacity for further growth. The firm has a history of strategic collaborations, such as the one with China Everbright Limited in 2016, focusing on industrial investment and real estate investment. Zhangjiang Haoheng's portfolio includes companies like LaNova Medicines Technology (Shanghai) Co., Ltd., which completed a CNY 300 million Series C1 financing round in 2024, with participation from Zhangjiang Haoheng. The firm's investment approach is characterized by a focus on technological innovation and a commitment to supporting the growth of emerging companies in various sectors.